Immune Design begins processing in LV305 Phase 1 clinical trial for cancer

Immune Design begins processing in LV305 Phase 1 clinical trial for cancer -

Immune Design, an immunotherapy clinical stage company focused on the development of immune-based therapies news for cancer and other chronic diseases, today announced treatment of the first patient in a clinical trial phase 1 LV305, an experimental agent immuno-oncology DCVex ^TM lentiviral platform vector society.

Phase 1 open-label, multicenter trial (NCT02122861) is designed to evaluate the safety, tolerability and immunogenicity of the LV305 in patients with locally advanced cancer, recurrent or metastatic, melanoma , cancer non-small cell lung cancer, ovarian cancer or sarcoma. The trial will enroll up to 36 patients in several clinical centers in the United States.

"Promoting new immuno-oncology agents such as LV305 that induce specific tumor in vivo T -cell response is promising for developing new and targeted approaches to treating cancer, "said Seth M. Pollack, MD, principal investigator at the Fred Hutchinson cancer research Center.

"LV305, which targets the antigen NY- ESO-1 expressed in a number of tumors provides a target, tumor-specific in vivo approach to the activation of a immune response of T cells that we believe may provide benefits to a wide range of cancer patients, "said Carlos Paya, MD, Ph.D., President and Chief Executive immune design. "LV305 is part of our prime-boost strategy that is designed to provide a superior approach to the fight against cancer. The test data will include immunogenicity, and early indications of effectiveness, and is intended to support LV305 combination with a second agent owner, G305, our prime-boost strategy known as CMB305. We plan to begin a Phase 1 trial for CMB before the end of 2014. "

"I am pleased to see that a novel idea and perhaps daring has matured into a product candidate undergoing clinical evaluation, and we believe that using a new vector of this type to provide genetic information specific to dendritic cells opens a new avenue which is very promising for the treatment of cancer, "said David Baltimore, Ph.D., President Emeritus, Robert Andrews Millikan Professor of biology, California Institute of Technology.